New Findings from Virginia Commonwealth University Describe Advances in Metabolic Syndrome (Safety and Efficacy of Topiramate In Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome the Topcspn Randomized Clinical...).

Předmět:	PERIPHERAL neuropathy METABOLIC syndrome TOPIRAMATE NERVE fibers CARBONIC anhydrase inhibitors
Zdroj:	Diabetes Week; 12/11/2023, p1063-1063, 1p
Abstrakt:	A recent report from Virginia Commonwealth University discusses the findings of a clinical trial on the use of topiramate in individuals with cryptogenic sensory peripheral neuropathy (CSPN) and metabolic syndrome. The trial aimed to determine if topiramate could slow the decline in nerve fiber density and improve neuropathy-specific quality of life. The study involved 132 participants who were randomly assigned to receive either topiramate or a placebo. The results showed that topiramate did not significantly affect nerve fiber density or quality of life in the intention-to-treat analysis, but a per-protocol analysis showed some improvement in quality of life among compliant participants. Overall, the study suggests that topiramate may not be an effective treatment for CSPN. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu